Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives
Stakeholders deemed "wider implications of diagnostic results", "feasibility", and "test journey" the most important considerations for decision-making about targeted profiling vs. CGP alongside clinical benefit and costs. For policy decision-making, it is important to understand the arguments behind the heterogeneous opinions, often related to the setting they originate from.
Authors
- Ellen G. Engelhardt (ORCID: https://orcid.org/0000-0003-0016-4972)
- Wim H. van Harten (ORCID: https://orcid.org/0000-0001-9580-0489)
- Valesca P. Retèl (ORCID: https://orcid.org/0000-0002-5624-3234)
- Lucas F. van Schaik
Institutions
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Erasmus University Rotterdam (NL)
- University of Twente (NL)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1186/s12885-024-13167-9
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- Ministerie van Volksgezondheid, Welzijn en Sport
- Zorginstituut Nederland